Physician profile
Suresh Devineni
NPI 1033301858
$18,318.41
in general payments reported to CMS, 2019-2025
38 companies · $3,605 in 2025
The $3,605 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $452 · 2021: $1,259 · 2022: $3,433 · 2023: $5,539 · 2024: $3,532 · 2025: $3,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,450 · Travel and Lodging: $2,370 · Food and Beverage: $2,337 · Honoraria: $400 · Education: $79.45 · Gift: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,450.00 |
| Travel and Lodging | $2,370.20 |
| Food and Beverage | $2,336.60 |
| Honoraria | $400.00 |
| Education | $79.45 |
| Gift | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Oncology Corporate, INC. | $3,266.00 | 2022-2023 | |
| Onmark, INC. | $2,757.94 | 2025 | |
| Daiichi Sankyo INC. | $2,531.69 | 2019-2025 | Vanflyta, Injectafer |
| Astrazeneca Pharmaceuticals LP | $2,138.29 | 2019-2024 | Imfinzi, Lynparza, Calquence |
| Beigene USA, INC. | $1,925.00 | 2024 | Brukinsa |
| Kite Pharma, INC. | $1,600.00 | 2022 | |
| Aveo Pharmaceuticals, INC. | $1,365.00 | 2023 | Fotivda |
| Beigene, LTD. | $525.00 | 2021 | |
| Pfizer INC. | $426.00 | 2021-2025 | |
| Athenex Pharmaceutical Division, LLC | $325.00 | 2020 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Mckesson Specialty Care Distribution, LLC | $117.31 | 2019 | |
| Genzyme Corporation | $105.00 | 2019 | |
| Cardinal Health 110 LLC | $100.00 | 2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $65.37 | 2021-2025 | |
| Puma Biotechnology, INC. | $59.73 | 2019-2025 | |
| Celgene Corporation | $55.33 | 2019 | |
| Acrotech Biopharma INC. | $51.89 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $50.44 | 2019-2021 | |
| Astellas Pharma US INC | $48.50 | 2019-2025 | Padcev, Xtandi |
| Amgen INC. | $30.22 | 2019 | |
| Exelixis INC. | $30.22 | 2019 | |
| Seagen INC. | $30.10 | 2021-2023 | Tukysa |
| Taiho Oncology, INC. | $25.36 | 2023 | |
| Tesaro, INC. | $24.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $21.91 | 2023 | Tavalisse, Rezlidhia |
| Glaxosmithkline, LLC. | $17.61 | 2021 | |
| Eisai INC. | $16.69 | 2025 | |
| Caris Mpi, INC. | $15.87 | 2025 | Mi Cancer Seek |
| Aurobindo Pharma USA, INC. | $15.39 | 2020 | |
| Genmab U.S., INC. | $13.98 | 2024 | Epkinly |
| Accord Healthcare, INC. | $13.74 | 2022 | |
| Abbvie INC. | $13.52 | 2025 | |
| Janssen Biotech, INC. | $12.16 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Devineni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.